澳大利亚-新西兰自发性冠状动脉夹层队列研究:主要不良心血管事件与复发的预测因素
该多中心队列研究纳入23个澳新中心共586例经核心实验室确认的SCAD患者,分析MACE及复发的独立预测因素。中位随访21个月,MACE发生率为8.6%、复发率为3.6%。出院时口服抗凝、替格瑞洛联合阿司匹林、肌纤维发育不良及卒中史与更高MACE独立相关。
要点
- SCAD患者出院时口服抗凝与更高MACE独立相关(aHR 3.8)。
- 替格瑞洛联合阿司匹林与更高MACE及SCAD复发相关。
- 肌纤维发育不良和卒中史亦为MACE与复发的预测因素。
核心结论
- 研究结果支持SCAD主要由壁内出血所致的假说,更强的抗血小板治疗和抗凝治疗与不良心血管结局存在有害关联。
研究设计与样本
- 多中心队列研究,涉及23个澳大利亚和新西兰中心,纳入年龄≥18岁、经核心实验室判定确认的SCAD所致ACS患者。
- 共586例患者,其中505例(150例前瞻性、355例回顾性)经核心实验室确认SCAD,平均年龄52.2±10.6岁,女性占88.6%,白人占74.5%。
- 采用多变量Cox比例风险模型分析主要MACE结局的预测因素。
主要发现
- 长期随访(中位21个月)期间,MACE和SCAD复发分别发生于8.6%和3.6%的患者。
- 出院时口服抗凝(aHR 3.8,95%CI 1.6-9.3,P=.003)、替格瑞洛联合阿司匹林(aHR 1.8,95%CI 1.04-3.2,P=.037)、肌纤维发育不良(aHR 2.2,95%CI 1.05-4.5,P=.037)及卒中史(aHR 3.8,95%CI 1.2-12.2,P=.03)与更高MACE独立相关。
- 肌纤维发育不良(aHR 3.9,95%CI 1.5-26.5,P=.01)、替格瑞洛联合阿司匹林(aHR 2.6,95%CI 2.1-5.3,P=.01)及卒中史(aHR 6.2,95%CI 1.8-9.5,P=.01)亦与更高SCAD复发相关。
临床怎么用
- 对SCAD患者应谨慎评估出院时口服抗凝及替格瑞洛联合阿司匹林的使用,因其与更高MACE和复发相关。
- 对合并肌纤维发育不良或卒中史的SCAD患者,需加强随访和风险评估。
局限性
- 研究包含部分回顾性纳入患者,可能存在选择偏倚。
- 随访时间中位21个月,长期结局需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of acute coronary syndrome (ACS). Recent data suggest a harmful association of dual antiplatelet therapy compared with single antiplatelet therapy following SCAD. This study investigated independent predictors of major adverse cardiovascular events (MACEs) and recurrence in patients with SCAD. METHODS: This multicentre cohort study involving 23 Australian and New Zealand sites included patients aged ≥18 years with an ACS due to SCAD confirmed on core laboratory adjudication. Multivariable Cox proportional hazard models analysed predictors for the primary MACE outcome. RESULTS: Among 586 patients, 505 (150 prospective, 355 retrospective) with SCAD confirmed by core laboratory adjudication, mean age was 52.2 ± 10.6 years, 88.6% were female, and 74.5% were Caucasian. At long-term follow-up (median 21 months), MACE and SCAD recurrence occurred in 8.6% and 3.6% of patients, respectively. Oral anticoagulation on discharge [adjusted hazard ratio (aHR) 3.8, 95% confidence interval (CI) 1.6-9.3, P = .003], ticagrelor combined with aspirin (aHR 1.8, 95% CI 1.04-3.2, P = .037), fibromuscular dysplasia (aHR 2.2, 95% CI 1.05-4.5, P = .037), and history of stroke (aHR 3.8, 95% CI 1.2-12.2, P = .03) were independently associated with higher MACE. Fibromuscular dysplasia (aHR 3.9, 95% CI 1.5-26.5, P = .01), ticagrelor combined with aspirin (aHR 2.6, 95% CI 2.1-5.3, P = .01), and history of stroke (aHR 6.2, 95% CI 1.8-9.5, P = .01) were also associated with higher SCAD recurrence. CONCLUSIONS: The findings support the hypothesis that SCAD is primarily caused by intramural bleeding, with a harmful association of more potent antiplatelet therapy and anticoagulation with adverse cardiovascular outcomes.
引用
- Dang, Psaltis, Burgess, et al. The Australian-New Zealand spontaneous coronary artery dissection cohort study: predictors of major adverse cardiovascular events and recurrence. Eur Heart J. 2025. PMID: 40049585. doi:10.1093/eurheartj/ehaf097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。